LENZ Therapeutics Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenues: $5.5 million, comprising:

Product Revenue: $1.7 million from approximately 27,000 monthly packs sold (9% increase from Q1).

License Revenue: $3.8 million from global partnership agreements, including milestone payments.

Operating Expenses:

Cost of Sales: $300,000 with expectations of 90% gross margin over time.

SG&A Expenses: $39.4 million (adjusted to $34.9 million excluding stock-based compensation), a 14% decline from Q1.

R&D Expenses: $0, consistent with prior quarters.

Net Loss: $31.9 million, translating to a net loss per share of $1.02.

Cash Position: Approximately $220 million in cash, cash equivalents, and marketable securities.

2Strategic Updates and Business Highlights

Launch Initiatives:

Telehealth services launched in July, aimed at improving patient access and convenience.

National TV advertising campaign initiated to enhance consumer awareness.

Patient Adoption:

Over 60% of e-pharmacy patients purchased more than one multipack of VIZZ, indicating strong early refill trends.

Average annualized purchase rate among early cohorts is approximately 5 monthly packs.

Global Expansion: Partnerships established in over 20 countries, with 9 regulatory submissions under review, including a new agreement in Australia and New Zealand.

3Forward Guidance and Outlook

The company is focused on translating early positive trends into sustained growth, emphasizing disciplined capital allocation towards initiatives that drive durable patient adoption.

Continued assessment of commercial strategies in Q3 to optimize investment based on performance metrics.

4Bad News, Challenges, or Points of Concern

Retail Channel Performance: Limited visibility and poor performance in the retail channel, making it difficult to assess refill dynamics outside the e-pharmacy.

Competitive Pressures: While VIZZ is showing promising refill rates (42% compared to competitors like VUITY), the overall market for presbyopia treatments remains competitive, and the company must continue to differentiate itself.

Patient Journey Complexity: The multi-step patient journey from awareness to treatment initiation presents challenges, with potential drop-offs at various stages.

5Notable Q&A Insights

Refill Dynamics: The refill rate for VIZZ is significantly higher than competitors, indicating strong product efficacy and patient satisfaction.

Telehealth Safety: The telehealth process includes stringent screening by licensed eye care professionals, ensuring patient safety and appropriateness for VIZZ.

Impact of Advertising: The national TV campaign is already showing positive effects on prescription growth across all channels, not just telehealth.

Patient Demographics: The patient mix remains stable, predominantly consisting of women aged 45-55, with no significant shifts observed since the DTC campaign launch. Overall, LENZ Therapeutics is navigating a promising trajectory with its VIZZ product, bolstered by strategic initiatives and early positive patient engagement metrics, while remaining vigilant about competitive pressures and operational challenges.